Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of LY3202626
NCT03023826Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2017
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LY3202626 in Alzheimer's disease (AD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Drug Concentration, Area Under the Concentration Versus Time Curve From Time Zero to Infinity and 1 more. Started Jan 2017; status: completed.
02
Drugs
LY3202626
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03023826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03023826.